![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 1873-5576|4|5|455-461
ISSN: 1568-0096
Source: Current Cancer Drug Targets, Vol.4, Iss.5, 2004-08, pp. : 455-461
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
UroOncology, Vol. 4, Iss. 1, 2004-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer
Drugs & Aging, Vol. 20, Iss. 2, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Do antiandrogens improve survival in prostate cancer?
Inpharma, Vol. 1, Iss. 1236, 2000-01 ,pp. :